Actinium Pharmaceuticals (ATNM) Competitors $1.63 -0.05 (-2.98%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.03 (+1.78%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM vs. GNFT, TLSA, EPRX, CCCC, CGTX, ENTA, IPHA, NLTX, SXTC, and AARDShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include GENFIT (GNFT), Tiziana Life Sciences (TLSA), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), Cognition Therapeutics (CGTX), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), China SXT Pharmaceuticals (SXTC), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Its Competitors GENFIT Tiziana Life Sciences Eupraxia Pharmaceuticals C4 Therapeutics Cognition Therapeutics Enanta Pharmaceuticals Innate Pharma Neoleukin Therapeutics China SXT Pharmaceuticals Aardvark Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Does the media favor ATNM or GNFT? In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 1 articles in the media. GENFIT's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 1.46 indicating that GENFIT is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Positive GENFIT Very Positive Do analysts rate ATNM or GNFT? Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 176.07%. GENFIT has a consensus price target of $9.00, indicating a potential upside of 114.23%. Given Actinium Pharmaceuticals' higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in ATNM or GNFT? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of GENFIT shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ATNM or GNFT? Actinium Pharmaceuticals has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Is ATNM or GNFT more profitable? GENFIT's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% GENFIT N/A N/A N/A Which has preferable earnings and valuation, ATNM or GNFT? GENFIT has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.24GENFIT$76.77M2.74$1.63MN/AN/A SummaryGENFIT beats Actinium Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$50.85M$862.73M$5.79B$21.48BDividend YieldN/A4.84%5.69%3.53%P/E Ratio-1.171.1574.5929.70Price / SalesN/A27.04453.5451.37Price / CashN/A19.5637.0824.52Price / Book1.246.6912.154.58Net Income-$48.82M-$4.50M$3.28B$1.00B7 Day Performance3.16%8.91%0.99%0.66%1 Month Performance7.95%11.41%7.21%4.64%1 Year Performance-16.20%25.49%63.07%15.96% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals3.0655 of 5 stars$1.63-3.0%$4.50+176.1%-13.8%$50.85MN/A-1.1730Positive NewsShort Interest ↑GNFTGENFIT2.0673 of 5 stars$3.96+0.5%$9.00+127.3%+0.3%$197.01M$76.77M0.00120TLSATiziana Life Sciences0.5624 of 5 stars$1.62-2.4%N/A+103.4%$193.97MN/A0.008Short Interest ↑EPRXEupraxia Pharmaceuticals2.8533 of 5 stars$5.27-2.2%$11.00+108.7%+105.6%$193.82MN/A-6.2029News CoverageCCCCC4 Therapeutics2.9877 of 5 stars$2.71-0.4%$8.00+195.2%-54.5%$193.59M$35.58M-1.72150CGTXCognition Therapeutics2.8314 of 5 stars$2.40-8.0%$2.83+18.1%+288.3%$191.90MN/A-3.5820Short Interest ↑ENTAEnanta Pharmaceuticals4.1772 of 5 stars$8.91+0.7%$22.25+149.7%-28.1%$189.20M$67.64M-2.06160IPHAInnate Pharma3.0209 of 5 stars$2.04-0.5%$11.00+439.2%-14.6%$188.97M$21.77M0.00220Positive NewsUpcoming EarningsGap DownNLTXNeoleukin TherapeuticsN/A$19.95+1.7%N/A-52.7%$187.49MN/A-6.4190High Trading VolumeSXTCChina SXT Pharmaceuticals0.8995 of 5 stars$1.65+2.5%N/A-65.3%$186.80M$1.74M0.0090Short Interest ↓High Trading VolumeAARDAardvark Therapeutics3.6915 of 5 stars$8.20-4.7%$32.60+297.6%N/A$186.59MN/A0.0018News Coverage Related Companies and Tools Related Companies GENFIT Alternatives Tiziana Life Sciences Alternatives Eupraxia Pharmaceuticals Alternatives C4 Therapeutics Alternatives Cognition Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Innate Pharma Alternatives Neoleukin Therapeutics Alternatives China SXT Pharmaceuticals Alternatives Aardvark Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNM Stock Alerts